Eton Pharmaceuticals sells its neurology portfolio to Azurity Pharmaceuticals, namely ET 101, ET 104 and ET 105 which are all under FDA review.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest